PentaOmix
Shedding Light on Cancer - Diagnosing cancer better and faster using hyperspectral data & AI
Company Overview
Snapshot
Founded in July 2020 by Boaz Brill and Yuval Garini, PentaOmix operates with 1–10 employees. The company has raised $2.27 million across one funding round and received a grant from the ATTRACT Project in February 2022.
Business overview
PentaOmix is developing a novel modality for digital pathology that aims to revolutionize cancer diagnosis and treatment matching. The company's system leverages hyperspectral imaging and AI algorithms to provide a deeper understanding of tumor microenvironments and a holistic view of tumor progression. PentaOmix serves the healthcare and life sciences sectors, including pharmaceutical companies, healthcare providers, and laboratories, with applications in oncology, diagnostics, and drug development.
Log in to access full profile ›Company Intelligence Q&A
- What is PentaOmix's core technology?
- PentaOmix develops a novel digital pathology system based on hyperspectral imaging and AI algorithms to analyze tumor microenvironments and progression, aiming to improve cancer diagnosis and drug matching.
- When was PentaOmix founded and by whom?
- PentaOmix was founded in July 2020 by co-founders Boaz Brill and Yuval Garini.
- What is the primary sector PentaOmix operates in?
- PentaOmix primarily operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics.
- What is PentaOmix's product stage?
- PentaOmix's product, PentaVision, is currently in the Research and Development (R&D) stage, focusing on advancing its novel digital pathology system.